Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine for Myotonic Dystrophy Type-1
NCT01406873Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Jun 2011
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) comparing Mexiletine with Placebo (2 arms). Primary endpoint: Mean Change From Baseline in Ambulation Using the 6 Minute Walk Distance at 6 months. Started Jun 2011; status: completed.
02
Drugs
mexiletine
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT01406873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01406873.